IM­brave150: Roche’s reg­u­la­to­ry crew plans a glob­al roll­out of Tecen­triq com­bo for liv­er can­cer as PhI­II scores a hit

Just weeks af­ter Bris­tol-My­ers Squibb de­fend­ed its failed piv­otal study pit­ting Op­di­vo against Nex­avar in liv­er can­cer, Roche says it’s beat the front­line chal­lenge with a com­bi­na­tion of their PD-L1 Tecen­triq with Avastin. And now they’re rolling their reg­u­la­to­ry teams in the US, Eu­rope and Chi­na in search of a new ap­proval — bad­ly need­ed to boost a trail­ing fran­chise ef­fort.

Giv­en their break­through and Big Phar­ma sta­tus as well as the use of two ap­proved drugs, FDA ap­proval may well prove to be some­thing of a for­mal­i­ty. And the Chi­nese have been clear that they want new drugs for liv­er can­cer, where lethal dis­ease rates are par­tic­u­lar­ly high.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.